According to the market research, the sales of PEG-rhG-CSF in the Chinese market have increased year by year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from CNY126 million in 2016 to CNY449 million in 2017, with an annual growth rate of 256.08%. The main reason for the sharp increase is that PEG-rhG-CSF was included in China Medical Insurance in 2017 and the approval of indication was leukemia. The price reduction led to a large increase in sales. The CAGR of sales of PEG-rhG-CSF is about 97.58% from 2016 to 2020.
The analyst analyzes that the sales volume of PEG-rhG-CSF will keep a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed every year. This situation led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficiency, and approval of indications. In addition, due to the use of PEG-rhG-CSF for non-medullary malignant tumors, the number of indications approved for China's medical insurance is likely to rise, and the sales and the sales volume will also have the potential to grow.
Topics Covered:
- The impact of COVID-19 on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Sales value of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020
- Competitive landscape of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China
- Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by regions and manufacturers
- Analysis of factors affecting the development of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Prospect of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market from 2021 to 2025
Table of Contents
Samples
LOADING...
Companies Mentioned
- Shiyao Group Baike biopharmaceutical Co., Ltd.
- Qilu Pharmaceutical Co., Ltd
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 50 |
Published | May 2021 |
Forecast Period | 2016 - 2025 |
Estimated Market Value ( CNY | CNY 125.97 Million |
Forecasted Market Value ( CNY | CNY 3091.52 Million |
Compound Annual Growth Rate | 42.7% |
Regions Covered | China |
No. of Companies Mentioned | 2 |